| Literature DB >> 34133923 |
Laure-Anne Teuwen1, Laura P M H De Rooij2, Anne Cuypers2, Katerina Rohlenova2, Sébastien J Dumas2, Melissa García-Caballero2, Elda Meta2, Jacob Amersfoort2, Federico Taverna2, Lisa M Becker2, Nuphar Veiga2, Anna Rita Cantelmo2, Vincent Geldhof2, Nadine V Conchinha2, Joanna Kalucka2, Lucas Treps2, Lena-Christin Conradi2, Shawez Khan2, Tobias K Karakach2, Stefaan Soenen3, Stefan Vinckier2, Luc Schoonjans4, Guy Eelen2, Steven Van Laere5, Mieke Dewerchin2, Luc Dirix5, Massimiliano Mazzone6, Yonglun Luo7, Peter Vermeulen5, Peter Carmeliet8.
Abstract
Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted endothelial cells (ECs) and pericytes, co-opting cancer and myeloid cells in tumors growing via vessel co-option, has not been investigated at the single-cell level. Here, we use a murine AAT-resistant lung tumor model, in which VEGF-targeting induces vessel co-option for continued growth. Single-cell RNA sequencing (scRNA-seq) of 31,964 cells reveals, unexpectedly, a largely similar transcriptome of co-opted tumor ECs (TECs) and pericytes as their healthy counterparts. Notably, we identify cell types that might contribute to vessel co-option, i.e., an invasive cancer-cell subtype, possibly assisted by a matrix-remodeling macrophage population, and another M1-like macrophage subtype, possibly involved in keeping or rendering vascular cells quiescent.Entities:
Keywords: anti-angiogenic therapy; cancer cells; endothelial cells; macrophages; metastasis; pericytes; resistance; single-cell RNA sequencing; tumor angiogenesis; tumor vessel co-option
Mesh:
Year: 2021 PMID: 34133923 DOI: 10.1016/j.celrep.2021.109253
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423